secwatch.observer — SEC 8-K summary
======================================

Issuer:     IGC Pharma, Inc. (IGC)
CIK:        0001326205
Form:       8-K
Filed at:   2021-10-15T23:59:59+00:00
Accession:  0001185185-21-001484
Event type: other_material
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02, 5.07, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

IGC shareholders approve director election, ratify auditor, and authorize 3.5M share equity grant
--------------------------------------------------------------------------------

- Richard Prins elected as Class B director, term through 2024 annual meeting.
- Manohar Chowdhry & Associates ratified as independent auditor for fiscal 2022.
- Board authorized grant of up to 3,500,000 common shares to employees, advisors, directors, and consultants.
- Meeting turnout: 37,257,143 shares voted (≈73% of outstanding); 21,876,265 broker non-votes.
- All four proposals passed; adjournment proposal was unnecessary.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1326205/000118518521001484/0001185185-21-001484-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1326205/000118518521001484/indiaglob20211015_8k.htm
  HTML page:      https://secwatch.observer/filing/0001185185-21-001484

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer